Tirzepatide
GLP-1 / Metabolic research-only
Mechanism
No mechanism summary on file.
Identification
| CAS number | 2023788-19-2 |
|---|---|
| Molecular formula | C225H348N48O68 |
Safety
Same active ingredient as FDA-approved Mounjaro and Zepbound (Eli Lilly). FDA resolved the tirzepatide shortage December 19, 2024; 503A enforcement discretion ended April 22, 2025 and 503B March 19, 2025. Subject to the ITC General Exclusion Order on importation (Investigation 337-TA-1386, January 2025), which blocks tirzepatide API imports at the US border. April 30, 2026 FDA proposal would exclude tirzepatide from the 503B Bulks List. Research-market channel is unregulated.
Vendors selling Tirzepatide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | — | — | — | 65 |
| Nuscience Peptides | — | — | — | 60 |
| Elite Research USA | — | — | — | 53 |
| Pure Peptides | — | — | — | 53 |
| Skye Peptides | — | — | — | 53 |
| Peptide Sciences | — | — | — | 26 |
| Paradigm Peptides | — | — | — | 0 |
Research
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med (2025) · rct
source → Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Nicholls SJ, Pavo I, Bhatt DL, et al. · N Engl J Med (2025) · rct
source → Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA (2024) · rct
source → Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA Intern Med (2024) · cohort
source → Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, et al. · Am Heart J (2024) ·
source → Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Loomba R, Hartman ML, Lawitz EJ, et al. · N Engl J Med (2024) · rct
source → Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D, Onishi Y, Norwood P, et al. · JAMA (2022) · rct
source → Tirzepatide: A Systematic Update.
Forzano I, Varzideh F, Avvisato R, et al. · Int J Mol Sci (2022) · review
source → Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J, Wysham C, Frías JP, et al. · Lancet (2021) · rct
source → Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. · N Engl J Med (2021) · rct
source →